These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 19390192)
1. Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine. van Asseldonk DP; Kanis BM; de Boer NK; van Bodegraven AA Digestion; 2009; 79(4):211-4. PubMed ID: 19390192 [TBL] [Abstract][Full Text] [Related]
2. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981 [TBL] [Abstract][Full Text] [Related]
3. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Yenson PR; Forrest D; Schmiegelow K; Dalal BI Am J Hematol; 2008 Jan; 83(1):80-3. PubMed ID: 17696202 [TBL] [Abstract][Full Text] [Related]
4. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143 [TBL] [Abstract][Full Text] [Related]
6. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564 [TBL] [Abstract][Full Text] [Related]
7. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. Regueiro M; Mardini H J Clin Gastroenterol; 2002 Sep; 35(3):240-4. PubMed ID: 12192200 [TBL] [Abstract][Full Text] [Related]
8. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease. Lee YJ; Hwang EH; Park JH; Shin JH; Kang B; Kim SY Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):475-8. PubMed ID: 26735160 [TBL] [Abstract][Full Text] [Related]
9. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. de Boer NK; van Bodegraven AA; de Graaf P; van der Hulst RW; Zoetekouw L; van Kuilenburg AB Ther Drug Monit; 2008 Jun; 30(3):390-3. PubMed ID: 18520612 [TBL] [Abstract][Full Text] [Related]
10. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Ansari A; Aslam Z; De Sica A; Smith M; Gilshenan K; Fairbanks L; Marinaki A; Sanderson J; Duley J Aliment Pharmacol Ther; 2008 Sep; 28(6):749-57. PubMed ID: 18557988 [TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Kwan LY; Devlin SM; Mirocha JM; Papadakis KA Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898 [TBL] [Abstract][Full Text] [Related]
12. Thiopurines in Crohn's disease, is there something new? Miheller P; Lakatos PL Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1505-14. PubMed ID: 20919963 [TBL] [Abstract][Full Text] [Related]
13. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961 [TBL] [Abstract][Full Text] [Related]
14. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients. Almer SH; Hjortswang H; Hindorf U Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369 [TBL] [Abstract][Full Text] [Related]
15. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. Banerjee S; Bishop WP J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Markowitz JF Rev Gastroenterol Disord; 2003; 3 Suppl 1():S23-9. PubMed ID: 12684586 [TBL] [Abstract][Full Text] [Related]
17. Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn's disease patients. Liu Q; Wang Y; Mei Q; Han W; Hu J; Hu N Scand J Gastroenterol; 2016 Sep; 51(9):1093-9. PubMed ID: 27152547 [TBL] [Abstract][Full Text] [Related]
18. TPMT in the treatment of Crohn's disease with azathioprine. Lennard L Gut; 2002 Aug; 51(2):143-6. PubMed ID: 12117866 [TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Dubinsky MC; Reyes E; Ofman J; Chiou CF; Wade S; Sandborn WJ Am J Gastroenterol; 2005 Oct; 100(10):2239-47. PubMed ID: 16181376 [TBL] [Abstract][Full Text] [Related]
20. Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease. Park SK; Hong M; Ye BD; Kim KJ; Park SH; Yang DH; Hwang SW; Kwak MS; Lee HS; Song K; Yang SK Scand J Gastroenterol; 2016; 51(6):684-91. PubMed ID: 26863601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]